Pharmaceutical Technology

DECEMBER 15, 2022

The congenital fibrinogen deficiency (CFD) market is expected to grow at a compound annual growth rate (CAGR) of 1.7% through 2031, reaching over $800m across the three major markets (3MM: US, Germany, and Japan), according to GlobalData’s recent report: Congenital Fibrinogen Deficiency: Opportunity Assessment and Forecast.

Marketing 130

Marketing Production Genotype Development 130

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

FEBRUARY 24, 2023

According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (LAI-287 + semaglutide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Pharmaceutical Technology

APRIL 3, 2023

But while the pandemic hampered access to health care services, it also led to accelerated demand for digital health technologies that enabled women to access remote care during lockdowns, said Wafaa Hasan, GlobalData’s healthcare analyst at a Femtech-centric webinar held on March 30.

Regulation 130

Regulation Compliance Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JULY 28, 2022

Cobitolimod, an agent being developed for patients with moderate to severely active UC, has both a novel MOA and a route of administration that is unique among marketed agents. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

NOVEMBER 23, 2022

Innovations in biotechnology are advancing the biopharmaceutical market, enabling the treatment of complex diseases with next-generation therapeutics synthesised or extracted from a biological source. The city is also home to two research hospitals, Hamilton Health Sciences and St Joseph’s Healthcare Hamilton.

Marketing 130

Marketing Gene Therapy Life Science Manufacturing 130

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

FDA Approval 130

FDA Approval Production Compliance Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 10, 2023

Partly in response to such drugs, risk-sharing agreements (RSAs) have increased in popularity and aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans. GlobalData takes this opportunity to review the various types of RSAs and their evolution over time.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 20, 2023

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iptacopan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

JULY 28, 2022

Despite this, some key opinion leaders (KOLs) interviewed by GlobalData argued that LAIs should be prescribed as soon as possible, following first-episode psychosis or during early-stage schizophrenia. GlobalData forecasts that it will launch in the US and 5EU next year.

Nurses 246

Nurses Production Pharmacy Marketing 246

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Production 162

Production Regulation Clinical Trials Clinical Trials 162

XTalks

APRIL 19, 2024

According to GlobalData , the global AI in healthcare market was valued at $81.3 AI in medical imaging is a large segment driving the market. Current leaders in the CT imaging market include Philips, GE HealthCare and Siemens. According to GlobalData, Siemens and GE HealthCare lead with 33.5

Marketing 52

Marketing Radiology Development Manufacturing 52

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

MARCH 10, 2023

Lebanon’s ongoing economic crisis and changes in pricing strategies have caused monumental price hikes that impact market access. In Lebanon, the battle for access to medicines rages on and is further heightened by dramatic decreases to the healthcare budget last year.

Marketing 130

Marketing Branding Manufacturing Medicine 130

XTalks

FEBRUARY 5, 2024

GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK said it has secured about two-thirds share of the US market where nearly all of Arexvy’s sales were recorded. In addition to promoting uptake in the US, GSK and Pfizer are also focused on expanding in the global market.

Vaccination 59

Vaccination Vaccine Marketing Sales 59

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Life Science 162

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. Telehealth is especially important for improving healthcare accessibility in rural regions. Pharmacy chains have become the backbone for providing infrastructure to roll out telehealth services.

Dermatology 130

Dermatology Pharmacy Branding Marketing 130

Pharmaceutical Technology

DECEMBER 5, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has also since granted the Great Britain marketing authorisation of Lupkynis to treat adults with active LN. Adoption of Lupkynis in the European market will depend largely on pricing as well as reception by physicians.

FDA Approval 147

FDA Approval Compliance Trials Marketing 147

Pharmaceutical Technology

JANUARY 2, 2023

According to GlobalData, the latest event to affect BI-1361849’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 17 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

Drugs 100

Drugs Production Manufacturing Development 100

Pharmaceutical Technology

AUGUST 12, 2022

The aim of the programme is to expedite the development, assessment and review of medical devices in order to provide timely access to patients and healthcare providers. According to GlobalData’s Epidemiology & Market Size database, around 1.2 million people in the UK and 2.7

Clinical Trials 354

Clinical Trials Clinical Trials Marketing Development 354

Pharmaceutical Technology

DECEMBER 12, 2022

The data, which is collated from the GlobalData Pharma Intelligence Center’s Deals Database and PharmSource reports on these outsourcing relationships, provides a glimpse of not only the different players involved in the pharma supply value chain, but also the nature of the contracts that link them.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

Pharmaceutical Technology

MAY 2, 2023

There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications. Marketed bispecific antibodies are largely bispecific T-cell engagers (BiTEs), which work by directing T-cells to antigen-expressing tumour cells. Cost-related unmet needs also scored highly.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Go-to-market strategies. The challenge of providing adequate access to the peripheral EU markets is quite evident. Efforts have been made to change this.

Drugs 147

Drugs Medicine Marketing Development 147

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality. A new frontier in cancer research. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Gevokizumab’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity (NME).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

Pharmaceutical Technology

NOVEMBER 24, 2022

This shift will be driven by the future of work and digital transformation initiatives ongoing across sectors ranging from retail to healthcare and financial services. Listed below are the key macroeconomic trends impacting the metaverse theme, as identified by GlobalData. Metaverse hype. Consumer adoption. Enterprise adoption.

Branding 130

Branding Development Marketing Regulation 130

Pharmaceutical Technology

MAY 26, 2023

Rinvoq is expected to have a rapid uptake in the CD market by healthcare providers (HCPs) due to the overall positive sentiment associated with this therapy.

FDA Approval 130

FDA Approval Trials Production Marketing 130

pharmaphorum

APRIL 20, 2021

Kesimpta was one of the first medicines to be review under the new Medicines and Healthcare products Regulatory Agency (MHRA) authorisation process following the UK’s departure from the EU at the start of the year. GlobalData thinks Ocrevus will remain the most widely-used option, hitting $7.6 billion by 2028. billion in sales in 2028.

Sales 111

Sales Medicine Drugs Marketing 111

Pharmaceutical Technology

JUNE 23, 2022

This shift will be driven by the future of work and digital transformation initiatives ongoing across sectors ranging from retail to healthcare and financial services. Listed below are the key macroeconomic trends impacting the metaverse theme, as identified by GlobalData. Metaverse hype. Consumer adoption. Enterprise adoption.

Branding 130

Branding Development Marketing Regulation 130

pharmaphorum

APRIL 23, 2021

Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the Plateau of Productivity. Dominic Tyer is a journalist and editor specialising in the pharmaceutical and healthcare industries. FDA approvals.

Production 131

Production FDA Approval Regulation Trials 131